AKOYA BIOSCIENCES INC (AKYA)       11.01  +0.13 (+1.19%)

11.01  +0.13 (+1.19%)

US00974H1041 - Common Stock - After market: 11.01 0 (0%)


Fundamental Rating

2

Taking everything into account, AKYA scores 2 out of 10 in our fundamental rating. AKYA was compared to 66 industry peers in the Life Sciences Tools & Services industry. AKYA has a bad profitability rating. Also its financial health evaluation is rather negative. AKYA is quite expensive at the moment. It does show a decent growth rate.

Note: AKYA has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

The Piotroski-F score of AKYA is 2.00. This is a very weak score and indicates problems in health and profitability for AKYA.

VS Industry

Valuation

Valuation Rating

1

With a price book ratio of 5.57, AKYA is valued correctly.
AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKYA. No positive earnings are expected for the next year.
When comparing the price book ratio of AKYA to the average industry price book ratio of 2.48, AKYA is valued more expensive than its industry peers.
VS Industry

Price/Book (5.57) VS Industry: 22% outperformed.

51.37
0.32

Growth

Growth Rating

6

AKYA is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 11.31% yearly.
AKYA shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.10%.

The Revenue is expected to grow by 24.22% on average over the next 5 years. This is a very strong growth
The earnings per share for AKYA have decreased strongly by -88.22% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -88.22% 59.22% 27.5% 19.48% 11.31%
RevenueN/A N/A 35.1% 35.03% 30.45% 29.64% 24.22%

Health

Health Rating

2

A Current Ratio of 3.53 indicates that AKYA has no problem at all paying its short term obligations.
A Quick Ratio of 3.11 indicates that AKYA has no problem at all paying its short term obligations.
The Current Ratio is in line with the industry averages, which is at 4.77.
AKYA has a Quick Ratio comparable to the industry average, which is at 4.30.

Compared to an average industry Debt to Equity Ratio of 0.08, AKYA is requires more financing than its industry peers. 81% of its industry peers have a better Debt to Equity Ratio.
Based on the Altman-Z score of 1.02, we must say that AKYA is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of AKYA to the average industry Altman-Z score of 2.69, AKYA is less financially healthy than its industry peers.
AKYA has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for AKYA.
VS Industry

Debt/Equity (0.71) VS Industry: 19% outperformed.

3.88
0.00

Quick Ratio (3.11) VS Industry: 44% outperformed.

0.04
40.60

Current Ratio (3.53) VS Industry: 41% outperformed.

0.04
40.60

Altman-Z (1.02) VS Industry: 33% outperformed.

-152.47
23.50

Dividend

Dividend Rating

0

AKYA does not give a dividend.

AKOYA BIOSCIENCES INC11.01

NASDAQ:AKYA (1/27/2023, 7:00:00 PM)+0.13 (+1.19%)

After market: 11.01 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-07 2022-11-07/amc Earnings (Next) 03-13 2023-03-13
Inst Owners 37.6% Inst Owner Change 0.01%
Ins Owners 4.92% Ins Owner Change 10%
Market Cap 417.89M Analysts 86.15
Price Target 19.67 (78.66%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) -14.3%
Min EPS beat(2) -23.87% Max EPS beat(2) -4.72%
EPS beat(4) N/A Avg EPS beat(4) -22.14%
Min EPS beat(4) -48.64% Max EPS beat(4) -4.72%
Revenue beat(2) 2 Avg Revenue beat(2) 4.24%
Min Revenue beat(2) 3.81% Max Revenue beat(2) 4.67%
Revenue beat(4) 3 Avg Revenue beat(4) 4.52%
Min Revenue beat(4) -1.3% Max Revenue beat(4) 10.91%
PT rev (1m) 0% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.99
P/FCF N/A
P/OCF N/A
P/B 5.57
P/tB 11.49
EV/EBITDA N/A
EPS(TTM) -1.85 EY N/A
EPS(NY) -1.69 Fwd EY N/A
FCF(TTM) -1.51 FCFY N/A
OCF(TTM) -1.3 OCFY N/A
SpS 1.84 BVpS 1.98
TBVpS 0.96 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 59.56%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 2 Asset Turnover 0.4

Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.64%
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 3.11
Altman-Z 1.02
F-Score 2 WACC 10.13%
ROIC/WACC N/A Cap/Depr(3y) 95.49%
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -88.22% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -51.61%
EPS Next Y 59.22% EPS Next 2Y 27.5%
EPS Next 3Y 19.48% EPS Next 5Y 11.31%
Revenue growth 1Y 35.1% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q 39.89%
Revenue Next Year 35.03% Revenue Next 2Y 30.45%
Revenue Next 3Y 29.64% Revenue Next 5Y 24.22%
EBIT growth 1Y -154.4% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year -72.65%
EBIT Next 3Y -6.57% EBIT Next 5Y 0.3%
FCF growth 1Y -305.94% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -427.31%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA